Multiple Myeloma

Multiple myeloma (MM) is the plasma cells in bone marrow with malignant proliferation of monoclonal immunoglobulin characterized produce a clone of the blood disease. Mainly for myeloma cell proliferation, invasion and destruction of bone tissue and extramedullary other organizations, a bone pain, pathologic fractures, bleeding, anemia, and the large number of myeloma cells produce abnormal immune globulin (M protein) and emerging infections, high calcium hyperlipidemia, kidney disease, Hyperviscosity, amyloidosis, and so on. MM was particularly prevalent in the age of onset of middle-aged and older, 50-60 years old for more than 40 years rare. More men than women, the male to female ratio is about 2:1. Over the past 10 years, with the aging of society increasingly obvious that the incidence of the disease has risen in the world incidence rate 4 / 100,000 annually, the incidence rate in Asia slightly lower. MM tumor in all proportion to one percent, or blood tumors 10 percent. The natural course of the disease for 0.5-1 years after treatment was significantly prolonged survival time, can live 4-5 years or even 7-8 years, the median survival period of three years. The leading cause of death for the infection, renal failure and bleeding.